Search the Newsreel

AAMI|Acadian Asset Management Inc|Price:80.880|Chg%:+0.600

This article provides an overview of Acadian Asset Management Inc. (AAMI), highlighting its key financials, growth potential, and institutional confidence. Despite a recent positive stock performance, the company shows underlying weaknesses in fundamentals and technicals that do not fully support the current trend, with …

ACHC|Acadia Healthcare Company Inc|Price:34.510|Chg%:+0.500

Acadia Healthcare Company Inc. (ACHC) is trading at $34.51, up 1.47%, with high growth potential and institutional ownership. While its valuation is considered fairly valued within the Healthcare Providers & Services industry, technical indicators suggest sideways trading despite strong recent performance and analyst "Buy" …

Acadia Realty Trust expected to post earnings of 5 cents a share - Earnings Preview

Acadia Realty Trust is projected to report earnings of 5 cents per share. This information comes from a Refinitiv earnings preview. Readers can access the full news article by starting a 30-day free trial.

Acadian Asset Management Inc. Revenue Breakdown – NYSE:AAMI

Dimensional Fund Advisors LP Purchases 71,888 Shares of Academy Sports and Outdoors, Inc. $ASO

Dimensional Fund Advisors LP increased its stake in Academy Sports and Outdoors by 1.8% in Q1 2026, purchasing 71,888 shares to reach a total of 4,029,262 shares valued at approximately $227.4 million. The company reported better-than-expected earnings of $0.93 per share and a revenue …

Academy Sports + Outdoors Helps Families Win Back-to-School and Back-to-Sport with Thousands of Lower Prices on Brands Families Know and Trust

Academy Sports + Outdoors is providing extensive savings for back-to-school and back-to-sport shopping. The retailer is offering thousands of lower prices on popular brands for apparel, footwear, backpacks, and sports gear, helping families manage their budgets. Shoppers can also benefit from the myAcademy Rewards …

ACAD: Acadia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides an overview of Acadia Pharmaceuticals Inc. (ACAD) stock, including its current price, market capitalization, volume, and key financial fundamentals. It also highlights recent news such as FDA Fast Track designation for an Alzheimer's candidate and analyst expectations, alongside general market sentiment …

ACHC5055371 Bond Redemption Profile

This article provides a profile of the ACHC5055371 bond issued by Acadia Healthcare Company, Inc., detailing its redemption overview, type, date, and amount. It also highlights the importance of understanding the sinking fund schedule for callable bonds. The piece emphasizes accessing key redemption data …

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)

Healthcare analysts are showing bullish sentiment towards Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD), and Immunome (IMNM). Dyne Therapeutics received a reiterated Buy rating and a $44.00 price target from LifeSci Capital, while ACADIA Pharmaceuticals also had its Buy rating reaffirmed by BMO Capital with …

Acadian Asset Management (AAMI) Reports Next Week: Wall Street Expects Earnings Growth

Wall Street expects a year-over-year increase in earnings on higher revenues when Acadian Asset Management (AAMI) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its …

Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to Trade

Acadia Pharmaceuticals (ACAD) closed the last trading session at $24.96, gaining 6.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target …

Implied Volatility Surging for Acadia Realty Trust Stock Options

Implied volatility for Acadia Realty Trust (AKR) stock options is surging, particularly for the Dec 18, 2026 $17.5 Call, indicating market expectations of a significant price movement. Analysts currently rate AKR as a Zacks Rank #3 (Hold) with recent upward revisions in earnings estimates, …

Academy’s Aug. 1 Event Offers Up to $100 Cards to First 125

Academy Sports + Outdoors is launching a "Back-to-School and Back-to-Sport" campaign, offering a wide range of products at competitive prices, including national and private brands. A key highlight is the "Line-Up to Win" event on August 1st at all 117 Texas stores, where the …

ACHC5000265 Bond Risk Profile

This page on TradingView provides a bond risk profile for Acadia Healthcare Company, Inc. 5.5% 01-JUL-2028 (ACHC5000265 FINRA). It offers an overview of the bond's coupon, redemption, and risks, including a credit risk assessment with key metrics. The page also mentions access to exclusive …

ACHC5000265 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the ACHC5000265 bond issued by Acadia Healthcare Company, Inc. It details the bond's interest rate, payment schedule, and redemption risks. The current coupon rate is 5.50%, with the next payment expected on January 4, 2027.

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Exploring a 30% Potential Upside Amid Robust Growth

ACADIA Pharmaceuticals (NASDAQ: ACAD) is attracting significant investor attention with its focus on neurological and rare disease treatments, including NUPLAZID and DAYBUE. The company holds a robust market position with a $4.3 billion market capitalization, strong revenue growth, and an impressive return on equity. …

ETFs Investing in Acadia Realty Trust Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Acadia Realty Trust (AKR). The ETFs are sorted by their market value, providing details such as their weight of AKR, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year …

Acadia gains fast track status for remlifanserin in Alzheimer's disease psychosis

Acadia Pharmaceuticals has been granted Fast Track designation by the FDA for its investigational drug remlifanserin, which is being developed to treat psychosis in patients with Alzheimer's disease. This designation aims to expedite the development and review process for drugs addressing serious conditions with …

Academy Sports & Outdoors Sees FY Adj EPS $6.40-Adj EPS $6.80 >ASO

Academy Sports & Outdoors (ASO) has provided its financial outlook for the fiscal year, projecting adjusted earnings per share between $6.40 and $6.80. This forecast offers investors insight into the company's expected performance.

Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate

Acadia Pharmaceuticals announced that its investigational drug, remlifanserin, has received FDA Fast Track designation for treating hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The company is currently evaluating remlifanserin in phase II and phase III studies, with top-line phase II results expected …

Acadia Realty Trust (AKR) to Post Earnings on Tuesday

Acadia Realty Trust (AKR) is scheduled to report its Q2 2026 earnings on Tuesday, July 28th, with analysts expecting $0.0453 EPS and $92.36 million in revenue. The company has provided a full-year 2026 EPS guidance of $1.22 to $1.26. Wall Street maintains a "Moderate …

Stifel raises Acadia Pharmaceuticals price target on drug potential

Stifel increased its price target for Acadia Pharmaceuticals to $25.00 from $24.00, maintaining a Hold rating, based on its analysis of remlifanserin for Alzheimer's disease psychosis and Lewy body dementia psychosis. The firm acknowledges the drug's high-risk, high-reward profile while noting its mechanism is …

Acadia Pharmaceuticals Receives US FDA Fast Track Designation for Alzheimer's Disease Psychosis Treatment

Acadia Pharmaceuticals has received FDA Fast Track designation for remlifanserin, an investigational drug for Alzheimer's disease psychosis (ADP), highlighting the urgent need for new treatments for this condition. The company announced that enrollment for the Phase 2 RADIANT trial is complete, with topline results …

Lobbying Update: $700,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed

ACADIA PHARMACEUTICALS (ACAD) has disclosed $700,000 in lobbying expenditures for Q2 2026, targeting issues like the Inflation Reduction Act, various healthcare acts, and patient access to medicines in Medicare and Medicaid. Additionally, the article details recent insider trading activity with 16 sales and no …

Does Acadia Healthcare (ACHC) Joining the Russell 2000 Reframe Its Behavioral Health Investment Narrative?

Acadia Healthcare (ACHC) was moved from the Russell 1000 to the Russell 2000 Index, recategorizing it into the smaller-capitalization value universe. This shift is primarily technical, influencing its investor base and trading liquidity, but its impact on the company's fundamentals is less significant than …

Acadia Healthcare Company (ACHC) Proxy filing Summary

Acadia Healthcare Company (ACHC) has released its proxy filing summary for the annual meeting scheduled for May 6, 2026. Key proposals include electing three Class III directors, amending the incentive compensation plan to increase available shares, holding a non-binding advisory vote on executive compensation, …

Acadia Healthcare Company (ACHC) Barclays 28th Annual Global Healthcare Conference summary

Acadia Healthcare Company (ACHC) presented at Barclays' 28th Annual Global Healthcare Conference, highlighting leadership changes and an energized focus on patient care and operational execution, including filling 3,000 new beds. The company detailed a $200 million embedded EBITDA opportunity from underperforming new facilities due …

FDA Grants Fast Track Designation To Acadia Pharma's Remlifanserin For Alzheimer's Psychosis

(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) on Monday said the U.S. Food and Drug Administration has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Acadia said enrollment in the Phase 2 portion of …

JP Morgan Maintains ACADIA Pharmaceuticals (ACAD) Overweight Recommendation

JP Morgan has reiterated its Overweight rating for ACADIA Pharmaceuticals (NASDAQ: ACAD). The investment bank also maintained its price target of $33.00 for the company. This suggests JP Morgan's continued positive outlook on ACADIA Pharmaceuticals' stock performance.

ACADIA Pharmaceuticals (ACAD) Stock Trades At A Discount To Earnings But Faces Concentrated Risk

ACADIA Pharmaceuticals (ACAD) appears undervalued based on its P/E ratio, trading at 11.7x earnings compared to a biotech industry average of 17.3x and a fair estimated P/E of 19.0x. While strong performance has been mixed, the recent positive opinion from the European Medicines Agency …

Bessemer Group Inc. Boosts Stake in Academy Sports and Outdoors, Inc. $ASO

Bessemer Group Inc. has increased its stake in Academy Sports and Outdoors (ASO) by 12.2% in the first quarter, now holding 543,102 shares valued at approximately $30.7 million. Academy Sports reported strong quarterly earnings of $0.93 EPS and revenue of $1.44 billion, exceeding analyst …

Acadia Healthcare (ACHC) Stock May Stay Cheap As Options Signal A Big Move

Acadia Healthcare Company (ACHC) stock has risen significantly (141.4% year-to-date) but still appears undervalued based on several metrics, including a P/S ratio of 0.9x compared to an industry average of 1.4x. While options activity suggests expectations of bigger market swings, analyst narratives present both …

ACADIA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GAROFALO ELIZABETH A. - moomoo

This document is a statement of changes in beneficial ownership of securities for Director Elizabeth A. Garofalo at ACADIA Pharmaceuticals. Such statements are legally required to disclose transactions involving company stock by insiders.

Notice of 2026 Second Quarter Results Conference Call and Webcast for Analysts and Investors

Date:August 6, 2026 Time:1:00 PM (Eastern Time) EDMUNDSTON, New Brunswick, July 17, 2026 (GLOBE NEWSWIRE) -- Acadian Timber Corp. will release its 2026 second quarter results after market close on Wednesday, August 5, 2026, which will be available on our website at www.acadiantimber.com/financial-information/. The …

Academy Sports director Jeffrey C. Tweedy sells 1,200 shares for $57,600

Academy Sports director Jeffrey C. Tweedy sold 1,200 shares of common stock on July 16, 2026, for $48 per share, totaling $57,600. Following the transaction, Tweedy directly held 10,567 shares. The news was generated by AI using information from an SEC filing.

Form 4 Academy Sports Outdoors Inc For: 17 July By Investing.com

This article reports on a Form 4 filing for Academy Sports Outdoors Inc. related to July 17. Form 4 filings disclose changes in ownership of company stock by insiders. The article provides no further details on the specific transactions or individuals involved.